Introduction
============

Hepatocellular carcinoma (HCC), one of the most common and aggressive types of cancer, is the third leading cause of cancer mortality globally ([@b1-ol-0-0-5788]). Despite the previous achievements in diagnostic and therapeutic techniques, the prognosis of HCC remains unsatisfactory. The high postoperative recurrence rate and metastasis are the key reasons for poor prognosis. Consequently, understanding the regulatory mechanisms that control tumor-initiation and metastasis is important to improve patient survival.

Octamer 4 (Oct4; also termed POU5F1) is a member of the Pit-Oct-Unc (POU)-domain transcription factor family, and acts as master transcription factor involved in maintenance and regulation of the pluripotent state ([@b2-ol-0-0-5788]--[@b7-ol-0-0-5788]). Oct4 has been found to participate in tumorigenicity and tumor progression in various cancer cells such as breast, prostate, gastric, colorectal, non-small cell lung and bladder cancer, glioma and human endometrial adenocarcinoma ([@b8-ol-0-0-5788]--[@b13-ol-0-0-5788]). Previous studies have demonstrated that the expression level of Oct4 was increased in HCC, and significantly associated with poor prognosis ([@b14-ol-0-0-5788]--[@b16-ol-0-0-5788]). Nevertheless, there remain limited studies on the role of Oct4 in HCC.

Here, the present study examined the gene expression profile of Oct4 overexpressed Huh7 cell line in comparison with a control using a whole genome approach to identify Oct4-dependent genes. The present study detected the altered expression of 673 genes (fold-change ≥2), including CTBP2, DKK1, FZD4, FZD8, WNT2B, lymphoid enhancer binding factor 1 (LEF1), LIFR, SOCS1, SOS2, GAS1, JAG1, ACVR1C, LTBP1 and THBS1 which affect multiple signaling pathways linked with self-renewal and metastasis. Based on these findings, it is assumed that Oct4 not only maintains stemness properties, but also performs a key role in tumor metastasis in HCC.

The cancer stem cell (CSC) theory suggests that only a small proportion of cells with stem cell-like features are responsible for tumor initiation and maintenance. There have been abundant studies that support the existence of CSCs in tumors such as leukemia and prostate, liver, brain, colon and pancreatic cancer ([@b17-ol-0-0-5788]--[@b23-ol-0-0-5788]). Previous data demonstrates that CSCs perform a critical role in tumor initiation, growth, metastasis and therapeutic resistance ([@b24-ol-0-0-5788]--[@b26-ol-0-0-5788]). Studies have suggested that CSCs have common molecules and pathways regulating self-renewal and proliferation that are similar to pluripotent embryonic stem cells. It has been demonstrated that embryonic stem cell-associated transcription regulators perform an important role in carcinogenesis and malignant transformation ([@b27-ol-0-0-5788],[@b28-ol-0-0-5788]). The present data also shows that Huh7 cells overexpressing Oct4 exhibit increased ability of soft agar colonization, sphere formation and invasion. From this data, the present study aims to characterize the gene regulatory network governed by Oct4 that may be used to provide insights into the molecular mechanism of carcinogenesis and metastasis in HCC.

Materials and methods
=====================

### Cell culture

Huh7 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). MHCC97H cells were used, which were previously established in the Liver Cancer Institute, Zhongshan Hospital, Fudan University (Shanghai, China) ([@b29-ol-0-0-5788]). The cell lines were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C with 5% CO~2~ in air atmosphere. The DMEM and FBS were obtained from Gibco (Thermo Fisher Scientific Inc., Waltham, MA, USA).

### Oct4 containing lentiviral transfection

The human Oct4 coding region was cloned from human genomic DNA and was confirmed by sequencing. The polymerase chain reaction product was then subcloned into the plasmid pLV-EF1a-IRES-GFP (Sidansai, Shanghai, China), as previously described ([@b30-ol-0-0-5788]). The lentivirus was produced by transfecting the packaging plasmids as well as the transfer lentiviral plasmids into HEK-293T cells with Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific Inc., Waltham, MA, USA). After 48 h of transfection, medium containing Oct4 containing lentivirus was harvested and concentrated by ultracentrifugation at 30,000 × g. The concentrated lentivirus was stored at −80°C. Huh7 cells were infected with lentivirus at a multiplicity of infection of 10 overnight in the presence of 8 µg/ml of polybrene (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany). Subsequent to culturing for 96 h, the efficiency of infection was \>85% according to green fluorescent protein fluorescence as the internal control.

### Sphere formation assay

Huh7 cells were plated in a 6-well plate at a density of 400 cells/ml and cultured in a serum-free DMEM medium, supplemented with epidermal growth factor (20 ng/ml), basic fibroblast growth factor (20 ng/ml) and B-27 supplement (Gibco; Thermo Fisher Scientific, Inc.). The number of spheres per well was counted directly 14 days later using a DMI 3000B Leica microscope (magnification, ×200). The experiment was performed in triplicate.

### Soft agar colonization

For clone formation assay, 1 ml of 0.6% low melting point (LMP) agarose in complete medium was added to 1 well of a 6-well plate. The gel medium was left to become solid, and then single cell suspensions of Huh7 cells were mixed with LMP agarose in a final concentration of 0.3% aliquots of 1 ml containing 1,000 cells were plated onto a 6-well plate. Colonies containing \>50 cells were assessed subsequent to 14 days of incubation at 37°C. The experiment was performed in triplicate.

### Cell invasion assays

Cell invasion assays were performed in Transwell plates (Corning Life Sciences, Corning, NY, USA). Cells in 0.5 ml of serum-free DMEM were placed in the upper chamber which was pre-loaded with a layer of Matrigel (Sigma-Aldrich; Merck Millipore) on the upper surface, whilst the lower chamber was loaded with 0.8 ml medium containing 10% FBS. The total number of cells that invaded to the lower chamber were stained with Giemsa and counted subsequent to incubation in 37°C for 48 h. A total of 6 optimal visual fields were selected for counting.

### RNA preparation

Total RNA was extracted from cultured cells using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. RNA quantity and quality was assessed using an Agilent 2100 BioAnalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA). Only samples with an RNA integrity number average of 7--10 were used. For microarray analyses, the RNA was purified and amplified twice using the SenseAmp RNA Amplification kit (Ambion, Austin, TX, USA). The sense RNA was then labelled with the biotin-labeled antibody from the IVT Labeling kit (Affymetrix Inc., Santa Clara, CA, USA), followed by double stranded-cDNA clean up using Sample Cleanup Module (GeneChip; Affymetrix, Inc.) and fragmented RNA using fragmentation buffer (Qiagen, Inc., Valencia, CA, USA). The remaining RNA was reverse transcribed (RT) to cDNA for validation by quantitative polymerase chain reaction (qPCR). cDNA was generated in a 25 µl reaction volume using 2 ng of total RNA, Superscript III (0.2 µl/reaction), random hexamers (9 µg/reaction), 5 mM deoxynucleotides (0.5 µl/reaction) and 1X Superscript buffer (Invitrogen; Thermo Fisher Scientific, Inc.).

### Microarray analysis

The labeled cDNA was hybridized onto an HG U133 Plus 2.0 Array (Affymetrix, Inc.) according to the standard Affymetrix protocol. The HG U133 Plus 2.0 Array contained 54,675 probes that covered the expression of over 47,000 transcripts and variants. The arrays were scanned with the GeneChip_Scanner 3000 (Affymetrix, Inc.).

### RT-qPCR

RT-qPCR was performed using 2X SYBR-Green Mix (Bio-Rad Laboratories, Inc. Hercules, CA, USA) using an iQ5 Real-Time PCR instrument (Bio-Rad Laboratories, Inc.), and each sample was run in triplicate. The human GAPDH gene was selected as endogenous control for data normalization. Primers for the reference genes and the target genes were designed using Primer Express 3.0 (Applied Biosystems; Thermo Fisher Scientific, Inc.) with melting temperatures ranging from 58-61°C and amplification lengths between 80--100 bp. qPCR cycling conditions were: Initial denaturation at 95°C for 10 min; 40 cycles of 95°C for 30 sec, 60°C for 60 sec and 72°C for 30 sec; final melt at 60--95°C rising by 0.5°C each step. Each gene expression level was calculated by a log equation (2^−∆∆Cq^) ([@b31-ol-0-0-5788]). The used gene primer sequences are listed in [Table I](#tI-ol-0-0-5788){ref-type="table"}.

### Pathway analysis

The gene functional enrichment analysis was performed using DAVID Bioinformatics Resources ([@b32-ol-0-0-5788]) Specifically, the Functional Annotation Clustering tool was used to enrich the overrepresented Gene Ontology (GO) terms among the differentially expressed gene (DEG) list. The HT Human Genome U133 Plus Set was used as the background for the GO analysis. The GO terms subsequent to correction for FDR at P≤0.05 were selected for additional analysis. Array data were used to test whether entire groups of genes associated with specific pathways show differential expression. Pathways were taken from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (<http://www.kegg.jp/>).

### Western blot analysis

Total cell lysates were separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes using the conventional method. The membrane was blocked by 5% milk at room temperature for 1 h. The blotted membrane was then incubated with the antibodies for Oct4 (dilution, 1:1,000; catalog no., 2907; Epitomics, Burlingame, CA, USA), LEF1 (dilution, 1:1,000; catalog no., 2230; Cell signaling Technology, Inc., Danvers, MA, USA), E-cadherin (dilution, 1:1,000; catalog no., 610181; BD Pharmingen, San Diego, CA, USA), N-cadherin (dilution, 1:1,000; catalog no., 610921; BD Pharmingen) and GAPDH (dilution, 1:10,000; catalog no., KC-5G4; KangChen, Shanghai, China) in 5% milk. Subsequent to being washed 3 times in 0.1% TBS Tween-20, the membrane was additionally incubated with horseradish peroxidase-conjugated secondary antibody (dilution, 1:10,000; catalog no., 123-001-021; Jackson ImmunoResearch, West Grove, PA, USA) at room temperature for 1 h, and then washed again with 0.1% TBS Tween-20 3 times. Enhanced chemiluminescence prime western blotting detection reagents (GE Healthcare, Little Chalfont, UK) and ChemiDoc XRS^+^ system (Bio-Rad Laboratories, Inc.) were used to visualize the bands on the membrane.

### Immunofluorescence staining

For immunofluorescence staining, the treated cells seeded on glass slides were fixed with 4% paraformaldehyde (Sigma-Aldrich; Merck Millipore) for 15 min and permeabilized with 0.1% Triton X-100 for 15 min at room temperature. Subsequently, cells were washed with PBS and blocked with 2% bovine serum albumin for 1 h at room temperature. Cells were incubated with β-catenin antibody (dilution, 1:200; catalog no., Ab32572; Abcam, Cambridge, UK) and diluted in PBS at 4°C overnight. A negative control (primary antibody omitted) was processed in every experiment. The next day, cells were washed with PBS and incubated with working solution of Alexa Fluor 488-conjugated secondary antibody (dilution, 1:100; catalog no., 4408; Cell Signaling Technology, Inc., Danvers, MA, USA) at room temperature for 1 h. Subsequent to rinsing in PBS, the slides were imaged immediately with a DM2500 fluorescence microscope (Leica Microsystems GmbH, Wetzlar, Germany).

### Statistical analysis

Student\'s t-test was used to compare two groups of parametric variants. The data were analyzed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA) was used to draw the graphs. The data are expressed as the mean ± standard error of the mean from at least 3 repeats. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Overexpressed Oct4 enhanced CSC properties and invasion ability of Huh7 cells

Investigations into the biological effect of Oct4 on HCC cells, sphere formation, soft agar colonization and invasion were performed using Oct4 overexpressed Huh7 cells. It was found that Oct4 overexpressed Huh7 cells exhibited increased sphere formation, increased clone numbers in the soft agar colonization and increased invasion in the invasion assay ([Fig. 1](#f1-ol-0-0-5788){ref-type="fig"}). This evidence indicated that Oct4 may drive HCC cells toward a state closer to CSC with higher invasion ability.

The expression of multiple signaling pathway genes varied following Oct4 overexpression. The microarray data revealed 673 DEGs with a fold-change \>2 between the Oct4 overexpressed Huh7 and the control ([Fig. 2A](#f2-ol-0-0-5788){ref-type="fig"}). Among them, 371 genes were upregulated and 302 genes were downregulated (data not shown). Using the functional enrichment analysis of these DEGs, the present study found that a series of biological pathways components were differentially expressed ([Fig. 2B](#f2-ol-0-0-5788){ref-type="fig"}).

The majority of differentially expressed WNT signaling genes were found to be upregulated, including WNT2B (fc=2.0405), dkk1 (fc=3.0301), FZD4 (fc=2.9077), FZD8 (fc=2.0289), LEF1 (fc=2.3173), CCND3 (fc=2.2184) and CTBP2 (fc=3.4984).

Transforming growth factor-β (TGF-β) 2, as a member of the TGF-β superfamily, was downregulated (fc=0.4788). ACVR1C also teremd activin A receptor was upregulated (fc=2.191). As a type I receptor for the TGF-β family, ACVR1C can transduce signals by forming a complex with Nodal and ACVR2B. Oct4 overexpression also increases expression of other TGF-β signaling regulator such as LTBP1 (fc=2.1327) and THBS1 (fc=2.3411).

Examination of NOTCH pathway components revealed upregulation of JAG1 (fc=2.1993). Analysis of hedgehog signaling components showed upregulated level of GAS1 (fc=8.121).

It is worth noting that the CDH1 (encoded E-cadherin) was downregulated (fc=0.395) and functional loss of E-cadherin is regarded as one of the hallmark of epithelial-mesenchymal transition (EMT). In addition the EMT marker, transcription factor Twist Family BHLH transcription factor 1 (Twist1) was upregulated (fc=2.031).

The pathways that were significantly differentially expressed are listed in [Table II](#tII-ol-0-0-5788){ref-type="table"}, including the mitogen activated protein kinase, WNT, TGF-β, notch and hedgehog signal pathway.

Validation of the microarray gene expression profile was then performed by RT-qPCR analysis. The present study tested the expression levels of TGF-β, WNT, Notch and Hedgehog signaling pathway genes ([Fig. 3](#f3-ol-0-0-5788){ref-type="fig"}). The results of the RT-qPCR analysis for the DEGs were mostly consistent with the results from the microarray data analysis.

### Oct4 activated LEF1/β-catenin dependent WNT signaling pathway and induced EMT

The array data showed that LEF1, which is an important component of WNT signaling pathway, was upregulated; additional western blot analysis experiments proved that LEF1 was a target gene of Oct4 ([Fig. 4A](#f4-ol-0-0-5788){ref-type="fig"}). Considering LEF1 is an interaction partner of β-catenin and differential expression of β-catenin was not observed, additional investigation is required to confirm the localization of β-catenin. Immunofluorescence staining shows that Oct4 promotes the accumulation of nuclear β-catenin, which is the hallmark of WNT signaling activation ([Fig. 4B](#f4-ol-0-0-5788){ref-type="fig"}). The expression of classical markers of EMT including E-cadherin and N-cadherin were assessed by western blot analysis. In Huh7 and MHCC97H, inhibition of E-cadherin and elevation of N-cadherin were found when Oct4 was overexpressed ([Fig. 4A](#f4-ol-0-0-5788){ref-type="fig"}).

Discussion
==========

CSCs are a subpopulation of cancer cells that possess characteristics of normal stem cells in solid tumors. Self-renewal activity and pluripotency are the most notable hallmarks of CSCs. Studies have suggested that the molecular signatures of CSCs are similar to pluripotent ESCs ([@b27-ol-0-0-5788],[@b28-ol-0-0-5788]). The POU domain transcription factor Oct4 is a gatekeeper of self-renewal and critical regulator of a transcription factor network in human ESCs ([@b33-ol-0-0-5788],[@b34-ol-0-0-5788]). Downregulation of Oct4 expression or epigenetic silencing of the promoter blocks self-renewal and pluripotency and triggers differentiation programs, which indicates that Oct4 is essential to establish and maintain pluripotency in ESCs ([@b35-ol-0-0-5788]). It has also been confirmed that Oct4 expression is essential for CSC-like properties in various types of cancer ([@b36-ol-0-0-5788],[@b37-ol-0-0-5788]). The present study determined that HCC cells with Oct4 overexpression acquired a stronger ability in sphere formation, soft agar colonization and invasion compared with mock cells. This finding is in accordance with phenomena previously observed ([@b38-ol-0-0-5788]), indicating that CSC-like properties and metastasis were enhanced by Oct4 overexpression.

Normal stem cell self-renewal and differentiation is tightly controlled by multiple developmental pathways, such as WNT, Notch and Hedgehog. These signaling pathways also contribute to controlling cancer progression ([@b39-ol-0-0-5788],[@b40-ol-0-0-5788]). From the present array data, multiple signaling pathways including WNT, TGF-β, Notch and Hedgehog were all involved. Among these, the effect on WNT pathways is the most evident. The majority of differentially expressed WNT signaling genes were found to be upregulated, including WNT2B, FZD4, FZD8, LEF1, dkk1, CCND3 and CTBP2. The canonical WNT pathway is initiated by WNT protein binding to the Frizzled receptor on the cell surface. Signals downstream of these receptors lead to inactivation of GSK-3β, resulting in the nuclear accumulation of β-catenin, which activates the transcription of target genes in collaboration with the T-cell factor/lymphoid enhancer factor1 (Tcf/Lef1) family of transcription factor. By further western blot analysis, it was determined that Lef1 was upregulated by Oct4 in HCC cell lines. The expression of β-catenin was not effected but the β-catenin nuclear accumulation was observed in Oct4 overexpressed HCC cells. Since β-catenin does not contain a nuclear localization signal and evidence has emerged showing that β-catenin nuclear localization is regulated via interaction partners of β-catenin, the present study speculated that Oct4 increases the β-catenin nuclear accumulation through LEF1 to active the WNT signaling pathway ([@b41-ol-0-0-5788]).

From the microarray data, the present study also noticed that the Twist1 transcription factor was upregulated and the epithelial marker E-cadherin encoding by chd1 gene was downregulated. These findings suggest that Oct4 overexpression can induce epithelial-mesenchymal transition (EMT) process in HCC. EMT is a critical process involved in cancer progression and metastasis and mounting data has demonstrated that the acquisition of invasive characteristics of tumor is associated with the process ([@b42-ol-0-0-5788]--[@b44-ol-0-0-5788]). In addition, emerging evidence also suggests a role for EMT in generating CSC-like features ([@b45-ol-0-0-5788]--[@b47-ol-0-0-5788]). Therefore, it was assumed that Oct4 may enhance the CSC-like properties and metastasis by inducing the EMT process.

Notably, the canonical WNT pathway performs a key role in EMT initiation ([@b48-ol-0-0-5788]). Translocation of β-catenin from the adhesion junction to the nucleus lead to the loss of E-cadherin and EMT processes. The present findings therefore suggest that Oct4 enhance CSC-like property of HCC cells *in vitro*. Overexpressed Oct4 activates the LEF1/β-catenin dependent WNT signaling pathway to promote EMT. Oct4 promote HCC cell CSC-like property may be through activation of EMT. The present results presented novel mechanistic sight into an important role of Oct4 in HCC and suggest a potential application of Oct4 in HCC prognosis and treatment.
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![Oct4 expression enhances CSC property and invasion ability of HCC cell. (A) Oct4 enhances the abilities of sphere formation. (B) Oct4 enhances the abilities of soft agar colonization. (C) Oct4 enhances the abilities of Matrigel invasion. Graphs show the mean ± standard error of the mean from at least 3 experiments compared with mock cells. \*P\<0.05 was considered to indicate a statistically significant difference. Oct4, octamer 4; CSC, cancer stem cell; HCC, hepatocellular carcinoma; GFP, green fluorescent protein.](ol-13-04-2599-g00){#f1-ol-0-0-5788}

![Heat map of differential expression genes. (A) Heat map visualization of 673 significantly regulated probe sets. The columns represent samples, whilst rows represent genes. Color key indicates gene expression value: Green, lowest and red, highest. (B) A series of pathways components were differentially expressed.](ol-13-04-2599-g01){#f2-ol-0-0-5788}

![Validation of the gene expression profile of microarrays by reverse transcription-quantitative polymerase chain reaction. The results indicate that the DEG expression profile were mostly consistent with the microarray data analysis. The human GAPDH gene was selected as assay endogenous control for data normalization. Each gene expression level was calculated by a log equation (2^−∆∆Cq^). LEF1, wnt2B, FZD4, FZD8, CCND3, CTBP2, JAG1, GAS1, TGFβ2, ACVR1C, LTBP1 and THBS1 were upregulated following Oct4 overexpression. Graphs show mean ± standard error of the mean performed in triplicate. Oct4, octamer 4; GFP, green fluorescent protein; LEF1, lymphoid enhancer binding factor 1.](ol-13-04-2599-g02){#f3-ol-0-0-5788}

![Oct4 activates LEF1/β-catenin dependent WNT signaling pathway and induces EMT. (A) Western blot analysis of EMT marker and LEF1. LEF1 and N-cadherin was upregulated in Oct4 overexpression cell lines, and E-cadherin expression was inhibited. (B) Immunofluorescence analysis of β-catenin shows that nuclear accumulation was promoted in Oct4 overexpression cell lines. Oct4, octamer 4; LEF1, lymphoid enhancer binding factor 1; EMT, epithelial-mesenchymal transition; GFP, green fluorescent protein.](ol-13-04-2599-g03){#f4-ol-0-0-5788}

###### 

Primer sequences of genes used in the validation study.

  Gene     Primer sequence (5′-3′)
  -------- ---------------------------
  WNT2b    F: CCTTGTCTACTTTGACAACT
           R: GAACCTGCAGCCTTGTCCAA
  FZD4     F: TACCTCACAAAACCCCCATCC
           R: GGCTGTATAAGCCAGCATCAT
  FZD8     F: CTACGTGGGCAACCAGAGCC
           R: CGGATGCGGAAGAGGGACA
  LEF1     F: GACGAGATGATCCCCTTCAA
           R: CGGGATGATTTCAGACTCGT
  CCND3    F: TTTCCTGGCCTTCATTCTG
           R: ATCATGGATGGCGGGTAC
  CTBP2    F: CCACCTCATCAATGACTTTACC
           R: AAGGCTTTCTCGTCCACC
  TGFB2    F: ATCCCGCCCACTTTCTAC
           R: CCGTTGTTCAGGCACTCT
  ACVR1C   F: ACCTGCTATTGCTCATCG
           R: ACAGCCAACCCTAAGTCC
  LTBP1    F: ATTCCACATACTCCCACC
           R: TACCCACAGTTCCACAGC
  THBS1    F: AGGGACGATGACTATGCTG
           R: AGGACTGGGTGACTTGCT
  JAG1     F: CTACTGCGACTGTCTTCCC
           R: ACAGATACAGCGATAACCATT
  GAS1     F: ACTGCGGCAAAGTCTTCAACGG
           R: TGGGCATAGCCAGCATGTCCTC
  GAPDH    F: TCAAGAAGGTGGTGAAGCAG
           R: GAGGGGAGATTCAGTGTGGT

F, forward; R, reverse.

###### 

Distribution of differentially expressed genes in multiple signaling pathways by KEGG analysis.

  Pathway ID   Pathway name                                         Category                              DEGs                                                                                                                                                                      P-value
  ------------ ---------------------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------
  hsa04010     Mitogen activated protein kinase signaling pathway   Signal transduction                   IL1R2, MEF2D, TGFB2, RPS6KA5, IL1R1, PLA2G12B, IL1RAP, ETS1, DOCK1, DUSP6, SOS2, KRAS, RPS6KA5, PLA2G12B, RAP1A                                                           
  hsa04350     Transforming growth factor-β signaling pathway       Signal transduction                   SOS2, TGFB2, KRAS, HNF4A, ACVR1C, INHBB                                                                                                                                   0.002
  hsa04310     Wnt signaling pathway                                Signal transduction                   SOX4, WNT2B, FZD8, CDH1, FZD4, SOX6, TGFB2, TLE3, TLE4, LEF1, SOX9, DKK1, ACVR1C, POU5F1, SOX5                                                                            0.0079
  hsa04630     Jak-STAT signaling pathway                           Signal transduction                   SOCS1, SOS2, KRAS                                                                                                                                                         0.009
  hsa04330     Notch signaling pathway                              Signal transduction                   JAG1, HEY1                                                                                                                                                                0.1551
  hsa04340     Hedgehog signaling pathway                           Signal transduction                   GAS1                                                                                                                                                                      0.2011
  hsa04060     Cytokine-cytokine receptor interaction               Signaling molecules and interaction   CCL2, CXCL, SOCS1, IRS2, KRAS                                                                                                                                             
  hsa04530     Tight junction                                       Cell communication                    CLDN11, MYL6, JAM3, CLDN1, PVRL3, CEBPA, TGFB2, CLDN14                                                                                                                    0.0157
  hsa05200     Pathways in cancer                                   Cancers                               AKR1C1/AKR1C2, ALB, ANXA1, CD109, CD82, CDH1, CYP2C18, CD109, DKK1, E2F1, FGA, FGF2, FGL1, FOXQ1, GABRE, GJB1, GPC3, HPSE, HPX, IL8, IQGAP2, KNG1, KRAS, LEF1, LIF, MAG   
  hsa04062     Chemokine signaling pathway                          Immune system                         CCL2, CXCL12, GNAI1, KRAS                                                                                                                                                 
  hsa04610     Complement and coagulation cascades                  Immune system                         SERPING1, CD55, C3, CFI, C8B, C5, C8A, C8G                                                                                                                                
  hsa04670     Leukocyte transendothelial migration                 Immune system                         CLDN11, MYL6, JAM3, CLDN1, MMP16, VAV3, CXCL12, GNAI1, CLDN14, RAP1A, TIMP2                                                                                               0.0005
  hsa05322     Systemic lupus erythematosus                         Immune disorders                      KNG1, CREM, SOS2, C8B, KRAS, C5, C8A, C8G                                                                                                                                 0.0189
  hsa03320     PPAR signaling pathway                               Endocrine system                      IL1R2, NR2F1, NR0B2, SOS2, KRAS, IL1R1, IL1RAP                                                                                                                            
  hsa00010     Glycolysis/gluconeogenesis                           Carbohydrate Metabolism               ALDOB                                                                                                                                                                     0.0027
  hsa00330     Arginine and proline metabolism                      Amino acid Metabolism                 ASS1, ARG2, ARG1                                                                                                                                                          0.0016
